Note to Investors
Cingulate Therapeutics is a privately held biopharmaceutical company focused on the development of new products for the treatment of Central Nervous System and Neurobiological Disorders. Currently, Cingulate is developing two products for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
To share confidential information with prospective and current investors, Cingulate has created a Virtual Data Room (VDR), which houses all appropriate corporate, financial and scientific documents.
Our current offering is available to both private Accredited Investors and Institutional Investors.
If you are interested in reviewing confidential and proprietary information regarding our products, development plan, patents and the investment opportunity please use the form on our Contact Us page with the subject line “Request Access to the VDR” or email Lou van Horn, Chief Financial Officer directly at: email@example.com.
If you have already received credentials and wish to revisit the VDR, please CLICK HERE.
As a RETURNING user, enter your user email and password you previously selected. If it has been over 30 days, you will be asked to receive a simple 5 digit code via your cell phone. Remember to enter the 5-digit code in the text message, not the number the code came from.
Should you have any issues with VDR access, call us or if you prefer contact:
AppFolio SecureDocs 24/7: